한미약품

128940KOSPI

65.8 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40

News Sentiment19.8 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 21.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Pharmaceuticals operates in three segments: pharmaceuticals, APIs, and overseas pharmaceuticals. It produces and sells key drugs such as the hypertension treatment 'Amozaltan' and has a global presence through its API division, Hanmi Precision Chemicals, which holds international certifications like FDA. Its overseas subsidiary, Beijing Hanmi, focuses on pediatric medications and hypertension treatments in the Chinese market.

Number of Employees

2,382people

Average Salary

86.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

35.56Industry Average 15.000.0Point

2.4x industry avg (risky)

PBR

4.28Industry Average 1.200.0Point

3.6x industry avg (risky)

ROE

14.05Industry Average 8.005.5Point

1.8x industry avg (good)

Debt Ratio

7.70Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 13.9% (declining, 3yr)

Detailed News Sentiment

40 totalPositive 33Neutral 5Negative 2Average Sentiment Score 79

Positive
한미약품 품질문서 4000건, AI가 분석한다
AI 도입으로 한미약품의 품질 관리 효율성이 크게 향상될 것으로 예상됩니다.
Neutral
[기업기상도] 비 그치고 볕든 기업 vs 태풍 소식에 흔들린 기업
Neutral
[임상 업데이트] 온코닉테라퓨틱스 ‘자큐보’, 헬리코박터 제균 3상.....
한미약품과 직접 관련 없는 온코닉테라퓨틱스의 신약 임상 결과가 발표되었으나, 한미약품의 주식에 직접적인 영향은 미미함.

Detailed Momentum

52-week position5.0Point

52w mid range (55%)

Current 475,500Won52-week high 626,00052-week low 290,500

1-month return6.0Point

1m +21.15% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

31 totalPositive 0Neutral 31Negative 0

Neutral최대주주등소유주식변동신고서2026-08-28
Neutral[기재정정]투자판단관련주요경영사항 (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결)2026-08-26
Neutral투자판단관련주요경영사항2026-08-24
Neutral[기재정정]투자판단관련주요경영사항2026-08-21
Neutral[기재정정]투자판단관련주요경영사항2026-08-21